Latka logo
Neurogene logo

Neurogenerevenue & market cap

New YorkFounded 2018CEO Rachel McMinn

Public company

Neurogene is focused on developing life-changing genetic medicines for patients and families affected by rare, devastating neurological diseases.

neurogene.comLinkedInUpdated Sep 28, 2026
Annual revenue
Not disclosed
No public figure yet
Market cap
$569.9M
Sep 2026

Neurogene revenue

Neurogene has not published its revenue, and GetLatka has no sourced estimate yet. Know the figure? Send us a source.

Neurogene market cap

Neurogene is a public company. Its market capitalisation was $569.9M in September 2026.

Neurogene CEO

Rachel McMinn is CEO of Neurogene.

Neurogene FAQ

Is Neurogene publicly traded?

Yes. Neurogene is a public company, with a market capitalisation of $569.9M in September 2026.

Who is the CEO of Neurogene?

Rachel McMinn is the CEO of Neurogene.

Categories

How this page is sourced

Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.

Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Neurogene? Join the podcast